Cellular Biomedicine Group Gross Profit

Cellular Biomedicine Group posts a gross profit of $260K as of September 2020. That compares with $45K in the prior-year period — up 476.4% year over year. That is below the Healthcare sector average of $65B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Cellular Biomedicine Group's gross profit was $45K. The latest reading is $260K — a 476.4% year-over-year increase (period ending September 2020). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $65B is typical. Cellular Biomedicine Group's $260K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Cellular Biomedicine Group's financial statement story. At $260K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CBMG's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $65B), and (3) consistency with growth and profitability. This page covers the first two; Cellular Biomedicine Group's other metric pages and overview cover the third.